Marie-Pierre David, MSc

Lead statistician
GSK, Wavre, Belgium

Disclosure: GSK group of companies (Individual(s) Involved: Self): Employee, Shareholder

Presentation(s):

• 119 - A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated

  Oral Abstract

• 121 - A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

  Oral Abstract